Treats pulmonary arterial hypertension (PAH) (WHO Group 1). ANDA 208252, held by Watson Laboratories. Ambrisentan.
As of Nov 21, 2026, ANDA 208252 (Ambrisentan), held by Watson Laboratories, was first approved by FDA on Mar 28, 2019, with 6 approved supplements and 0 published complete response letters.
Ambrisentan tablets are indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in adult patients: To improve exercise ability and delay clinical worsening. In combination with tadalafil to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability. Studies establishing effectiveness included predominantly patients with WHO Functional Class IIโIII symptoms and etiologies of idiopathic or heritable PAH (60%) or PAH associated with connective tissue diseases (34%).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 28, 2019 | Original application | Approved |
| Ambrisentan5MG ยท tablet;oral | Ambrisentan | Rx |
| Ambrisentan10MG ยท tablet;oral | Ambrisentan | Rx |
| Feb 17, 2026 | Supplement 8Labeling ยท Standard review | Approved | None posted |
| Apr 4, 2025 | Supplement 7REMS | Approved | None posted |
| Aug 19, 2024 | Supplement 5REMS | Approved | None posted |
| Jun 8, 2021 | Supplement 4REMS | Approved | None posted |
| Dec 22, 2020 | Supplement 2REMS | Approved | None posted |
| Nov 29, 2019 | Supplement 1Labeling ยท Standard review | Approved | None posted |
| Mar 28, 2019 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters